Active substance: no-carrier-added (n.c.a.) Lutetium-177 (177Lu) chloride
EndolucinBeta® is a radiopharmaceutical precursor and it is indicated for the radiolabeling of disease-specific carrier molecules in nuclear medicine. These biomolecules have been specifically developed for the radiolabeling with this radionuclide. The emerging radio conjugate is applied in Targeted Radionuclide Therapy, frequently in cancer treatment e.g. for neuroendocrine tumors (NETs). EndolucinBeta® has a half-life of 6.647 days and provides the specific activity of more than 3,000 GBq/mg at Activity Reference Time (ART). EndolucinBeta® contains no metastable 177mLu.